Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Acquisition of Caliper Clears Anti-Trust Review

NEW YORK (GenomeWeb News) – PerkinElmer today said that its planned acquisition of Caliper Life Sciences has cleared anti-trust reviews in the US and Germany.

The $600 million deal, which was signed early last month, still requires the approval of Caliper's stockholders, among other remaining conditions. The firms previously said that they expect the transaction to close in the fourth quarter of this year, but they didn't provide an update to that expectation today.

The deal will broaden PerkinElmer's reach in the life sciences research space, providing the firm with Caliper's portfolio of imaging, microfluidics, automation, and sample preparation platforms and technologies. It also will combine Caliper's imaging instrumentation for in vivo imaging applications with PerkinElmer's broad offering of imaging reagents and set up the combined firm with further growth opportunities in molecular diagnostics.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.